X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ADCOCK INGRAM (S. Africa) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ADCOCK INGRAM
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ADCOCK INGRAM
Jun-14
NOVARTIS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs758367-   
Low Rs579265-   
Sales per share (Unadj.) Rs228.4109.1-  
Earnings per share (Unadj.) Rs31.7-27.5-  
Cash flow per share (Unadj.) Rs32.8-22.8-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.185.7-  
Shares outstanding (eoy) m24.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.9 101.2%   
Avg P/E ratio x21.1-11.5 -183.4%  
P/CF ratio (eoy) x20.4-13.9 -147.3%  
Price / Book Value ratio x2.23.7 61.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50553,291 31.0%   
No. of employees `0000.74.3 15.6%   
Total wages/salary Rs m1,4453,345 43.2%   
Avg. sales/employee Rs Th8,441.34,290.3 196.8%   
Avg. wages/employee Rs Th2,163.6779.1 277.7%   
Avg. net profit/employee Rs Th1,173.1-1,081.1 -108.5%   
INCOME DATA
Net Sales Rs m5,63918,418 30.6%  
Other income Rs m1,718129 1,332.2%   
Total revenues Rs m7,35718,547 39.7%   
Gross profit Rs m-63-3,192 2.0%  
Depreciation Rs m25795 3.2%   
Interest Rs m55499 11.1%   
Profit before tax Rs m1,575-4,357 -36.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792272 290.8%   
Profit after tax Rs m784-4,641 -16.9%  
Gross profit margin %-1.1-17.3 6.4%  
Effective tax rate %50.3-6.2 -804.2%   
Net profit margin %13.9-25.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m9,52213,490 70.6%   
Current liabilities Rs m3,2967,590 43.4%   
Net working cap to sales %110.432.0 344.7%  
Current ratio x2.91.8 162.5%  
Inventory Days Days37111 33.0%  
Debtors Days Days28124 22.9%  
Net fixed assets Rs m467,863 0.6%   
Share capital Rs m12386 144.3%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,33614,456 50.7%   
Long term debt Rs m05,080 0.0%   
Total assets Rs m11,10527,309 40.7%  
Interest coverage x29.5-7.7 -381.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.7 75.3%   
Return on assets %7.6-15.2 -49.8%  
Return on equity %10.7-32.1 -33.3%  
Return on capital %22.2-19.8 -112.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,6101,572 102.4%  
From Investments Rs m687-483 -142.3%  
From Financial Activity Rs m-2,6774,611 -58.1%  
Net Cashflow Rs m-3805,700 -6.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR

Compare NOVARTIS With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: DIVIS LABORATORIES  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - BIOCON LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS